相似文献
1
Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Neuro Oncol. 2010 Jan;12(1):14-8. doi: 10.1093/neuonc/nop010. Epub 2009 Oct 20.
2
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
N Engl J Med. 2009 Jul 23;361(4):358-67. doi: 10.1056/NEJMoa0902579. Epub 2009 Jul 8.
3
Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Otol Neurotol. 2012 Aug;33(6):1046-52. doi: 10.1097/MAO.0b013e31825e73f5.
4
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
J Clin Oncol. 2016 May 10;34(14):1669-75. doi: 10.1200/JCO.2015.64.3817. Epub 2016 Mar 14.
5
Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
J Laryngol Otol. 2012 Jan;126(1):79-82. doi: 10.1017/S0022215111002805. Epub 2011 Oct 18.
6
Hearing improvement after bevacizumab for neurofibromatosis type 2.
N Engl J Med. 2009 Oct 29;361(18):1809-10; author reply 1810-1. doi: 10.1056/NEJMc091694.
7
The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Eur Arch Otorhinolaryngol. 2015 Dec;272(12):3627-33. doi: 10.1007/s00405-014-3398-3. Epub 2014 Nov 25.
8
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Otol Neurotol. 2010 Sep;31(7):1135-43. doi: 10.1097/MAO.0b013e3181eb328a.
9
Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
Eur Arch Otorhinolaryngol. 2015 Dec;272(12):3857-60. doi: 10.1007/s00405-015-3604-y. Epub 2015 Mar 21.
10
Hearing improvement after bevacizumab for neurofibromatosis type 2.
N Engl J Med. 2009 Oct 29;361(18):1810; author reply 1810-1.
引用本文的文献
1
Bilateral vestibular schwannoma with a cooccurring meningioma in a child: a case report and review of literature.
Ann Med Surg (Lond). 2024 May 22;86(7):4247-4254. doi: 10.1097/MS9.0000000000002217. eCollection 2024 Jul.
2
Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions.
Oncol Ther. 2024 Jun;12(2):257-276. doi: 10.1007/s40487-024-00279-2. Epub 2024 May 17.
3
Long-term outcomes of stereotactic radiosurgery for intracranial schwannoma in neurofibromatosis type 2: a genetic analysis perspective.
J Neurooncol. 2024 Jan;166(1):185-194. doi: 10.1007/s11060-023-04530-0. Epub 2023 Dec 27.
4
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.
Neurooncol Adv. 2023 Sep 22;5(1):vdad123. doi: 10.1093/noajnl/vdad123. eCollection 2023 Jan-Dec.
5
Neurofibromatosis type1, type 2, tuberous sclerosis and Von Hippel-Lindau disease.
Childs Nerv Syst. 2023 Oct;39(10):2791-2806. doi: 10.1007/s00381-023-06160-3. Epub 2023 Oct 11.
6
A Novel Multi-Model High Spatial Resolution Method for Analysis of DCE MRI Data: Insights from Vestibular Schwannoma Responses to Antiangiogenic Therapy in Type II Neurofibromatosis.
Pharmaceuticals (Basel). 2023 Sep 11;16(9):1282. doi: 10.3390/ph16091282.
7
Current progress in genomics and targeted therapies for neurofibromatosis type 2.
Fukushima J Med Sci. 2023 Aug 10;69(2):95-103. doi: 10.5387/fms.2023-05. Epub 2023 Jul 19.
8
Schwannomas of Brain and Spinal Cord.
Adv Exp Med Biol. 2023;1405:331-362. doi: 10.1007/978-3-031-23705-8_12.
9
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
Neuro Oncol. 2023 Aug 3;25(8):1498-1506. doi: 10.1093/neuonc/noad066.
10
Qu-Du-San-Jie decoction induces growth inhibition and vascular normalization in NF2-associated vestibular schwannoma.
Front Pharmacol. 2022 Aug 19;13:941854. doi: 10.3389/fphar.2022.941854. eCollection 2022.
本文引用的文献
1
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
J Neurooncol. 2009 Feb;91(3):329-36. doi: 10.1007/s11060-008-9718-y. Epub 2008 Oct 25.
2
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. doi: 10.1038/ncponc1157. Epub 2008 Jun 17.
3
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.
4
Taming glioblastoma: targeting angiogenesis.
J Clin Oncol. 2007 Oct 20;25(30):4705-6. doi: 10.1200/JCO.2007.13.1037.
5
Expression of VEGF and its receptor genes in intracranial schwannomas.
J Neurooncol. 2007 Jul;83(3):259-66. doi: 10.1007/s11060-007-9336-0. Epub 2007 Feb 14.
6
Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates.
Neurosurgery. 2007 Mar;60(3):460-8; discussion 468-70. doi: 10.1227/01.NEU.0000255340.26027.53.
7
Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.
J Med Genet. 2006 Apr;43(4):289-94. doi: 10.1136/jmg.2005.036319. Epub 2005 Sep 9.
8
Multichannel auditory brainstem implant: update on performance in 61 patients.
J Neurosurg. 2002 Jun;96(6):1063-71. doi: 10.3171/jns.2002.96.6.1063.
9
The neuroimaging and clinical spectrum of neurofibromatosis 2.
Neurosurgery. 1996 May;38(5):880-5; discussion 885-6. doi: 10.1097/00006123-199605000-00004.
Zotero 插件